Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a 52-week observational study across Canada to evaluate the real-world impact, safety, and effectiveness of tildrakizumab in patients with moderate-to-severe plaque psoriasis who have Fitzpatrick skin types III and above. The study aims to provide valuable insights for optimizing care and addressing unmet needs in this diverse population. Since tildrakizumab was approved in 2018, its specific effects in Canadian patients have not been well documented. Participants will be patients starting tildrakizumab treatment as part of their routine care through the ILUMYA SUPPORT Program. The study will follow these patients over one year without altering their treatment, observing how tildrakizumab affects their quality of life and psoriasis severity. The research will monitor patient-reported outcomes and clinical assessments including the Dermatology Life Quality Index, Psoriasis Area Severity Index, Body Surface Area, and Physician Global Assessment at multiple points up to 52 weeks. Throughout the study, participants will attend scheduled visits to complete questionnaires about quality of life, sleep, discomfort, and skin pain, alongside routine clinical evaluations. The study will also track safety, patient adherence, and satisfaction with tildrakizumab. These comprehensive observations aim to correlate clinical improvements with quality of life enhancements, providing a broad understanding of treatment impact in everyday clinical practice.